Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Geneoscopy logo — Cancer Prevention | Diagnostics | Precision Medicine

Geneoscopy

Cancer Prevention | Diagnostics | Precision Medicine

Founded 2015 United States St. Louis, United States 60 employees Series B Total: $112.90M Biotechnology, Health Care

General Information

Company Name Geneoscopy
Founded Year 2015
Location United States St. Louis, United States
Employees 60
Industries Biotechnology, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Geneoscopy. To contact Geneoscopy, visit geneoscopy.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Geneoscopy compare?

A PDF of Geneoscopy and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Geneoscopy soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Geneoscopy

Geneoscopy is a biotechnology startup founded in 2015 and headquartered in the United States. The company's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Its lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. Notably, this device received a Breakthrough Device Designation from the FDA for its potential to reduce morbidity associated with colorectal cancer through advanced adenoma detection. This innovative approach has gained significant attention, resulting in a $105.00M Series B investment from a consortium of investors, including Cultivation Capital, BioGenerator, Innovatus Capital Partners, LabCorp, Lightchain, NT Investments, Morningside Venture Investments as of 16 November 2021. The company's strong focus on cancer prevention, diagnostics, and precision medicine positions it as a potential game-changer in the field. Moreover, Geneoscopy is not solely focused on colorectal cancer diagnostics. The company is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in collaboration with biopharmaceutical companies and leading academic research institutions. Overall, Geneoscopy's innovative diagnostic technologies, strong investor backing, and commitment to advancing gastrointestinal health make it a promising player in the biotechnology and healthcare industries.

Business keywords: Life Sciences, Noninvasive Diagnostic Screening, Colorectal Cancer Screening, GI Health, Precision Medicine, Companion Diagnostics, RNA Biomarkers, Inflammatory Bowel Disease (IBD)

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $105.00M 7
Cultivation Capital BioGenerator Innovatus Capital Partners
Cultivation Capital, BioGenerator +5
16 Nov 2021
Series A $6.90M 3
Cultivation Capital Lightchain
Cultivation Capital, Lightchain +1
02 Oct 2019
Seed Round $1.00M -
13 Apr 2018
Seed Round Undisclosed -
01 Oct 2016

Geneoscopy Alternatives & Competitors

View All Alternatives
Geneoscopy vs
Oxford Cancer Biomarkers
Oxford Cancer Biomarkers

Pioneering Precision Medicine

Grant
7 employees
Biopharma, Biotechnology
Geneoscopy vs
oncgnostics GmbH
oncgnostics GmbH Germany

Precision in Cancer Diagnostics

25 employees
Biotechnology, Health Care
Geneoscopy vs
Novigenix SA
Novigenix SA Switzerland

Leader in Immuno-Transcriptomic Precision Medicine solutions

Series B
26 employees
AI, Analytics
View all alternatives

FAQ About Geneoscopy

Cancer Prevention | Diagnostics | Precision Medicine
Geneoscopy was founded in 2015.
Geneoscopy is headquartered in St. Louis, United States.
Geneoscopy operates in Biotechnology and Health Care. Its work centres on Life Sciences, Noninvasive Diagnostic Screening, Colorectal Cancer Screening and GI Health.
Geneoscopy has approximately 60 employees.
Geneoscopy has completed 4 funding rounds, raising a total of $112.90M. The latest funding stage is Series B.
Top alternatives and competitors to Geneoscopy include Oxford Cancer Biomarkers, oncgnostics GmbH, Novigenix SA, Cambridge Epigenetix, Isabl Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Geneoscopy and Oxford Cancer Biomarkers are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Geneoscopy, https://bouncewatch.com/company/geneoscopy, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes